What Share Options Become When a Biotech Delists

A biotechnology company in Oslo, Norway — valued at about 77 million kroner, or roughly $6.5 million — just granted 1.3 million share options to its employees.

That was fine. The company has been listed on Euronext Growth Oslo for years. Share options are how clinical-stage biotechs compensate people: you get the right to buy stock at a set price, and if the company's drug program works and the stock goes up, those options become real money. It is the standard currency of the pre-revenue life sciences world.

Except this is the last batch of share options the company will ever issue as a public company.

On October 12, 2026, EXACT Therapeutics AS (EXTX) is being delisted from the Oslo exchange. The last day to trade its shares is October 9. The grant date was August 31.

The timing is not an accident. And the mechanics of what happens to those options after delisting are worth understanding, because this is a specific kind of corporate structure that investors — especially the ones who still own the stock and haven't sold into the dying trade — should have in their head.

What share options actually are

Share options are a promise from the company to you, the holder, that you can buy a new share at a fixed "exercise price" at any time during the vesting window. When you exercise, the company creates a new share, you pay the exercise price into the company's treasury, and the total number of shares in existence goes up. Existing shareholders own a slightly smaller percentage of the company.

The company benefits because it paid no cash. The employee benefits because — assuming the stock price rises above the exercise price — they can buy stock below market and immediately sell it on the open exchange.

That last word is the load-bearing one: the open exchange.

Share options are a compensation instrument that only works because there is a public market. There is a transparent price. There is liquidity. The employee exercises, buys at the fixed price, and sells at the market price on the same day. The spread is their compensation.

Without an exchange, share options don't disappear — but they become something different. They become a claim against a private company's future liquidity event. You still have the right to buy shares at the fixed price, but you can't sell them. There is no market price. There is no way to realize the value except through a sale of the company, a relisting, or a private buyout.

This is the structural change the delisting makes.

Why the timing

EXACT Therapeutics announced its intent to delist on May 29, 2026. The board's stated reasoning was straightforward: the company is clinical-stage, it has no revenue, and the costs of being publicly listed — compliance, reporting, exchange fees, governance overhead — outweigh the benefits for a company at this stage. A private company structure, the board said, gives management more room to work without the administrative burden.

The AGM approved the delisting on June 12. Oslo Børs confirmed the removal on June 30, setting October 12 as the effective date.

Then on August 31, 42 days before delisting, the company granted 1.3 million share options. Of those, 780,000 — exactly 60% — went to "primary insiders": the CEO, CFO, board members, and other executive officers. The remaining 520,000 went to other employees.

This is not a routine employee-compensation event. This is a deliberate restructuring of who holds claims on the company's equity, and at what price, just before those claims stop being marketable.

What the options are worth

The company didn't publish the exact exercise price in the press release. Norwegian exchange rules require the exercise price to be at or above the market price on the grant date. Given the stock has been trading in the NOK 0.60–0.80 range for months, the exercise price is roughly that range — though the exact number matters less than the structure.

Here is what to think about. Right now, someone holding those options can exercise them, buy shares at the exercise price, and sell those shares on Oslo Børs at the same price — if the market price is above the exercise price. After October 12, that chain of events stops working. The options still exist. The company still owes the holder the right to buy a share. But there is no exchange to sell it on.

For the insider recipients, that is probably fine. Insiders aren't trying to exercise and sell these options in September. They're holding them as a long-term stake — a way to say, "we're aligned with the company's future." If EXACT Therapeutics sells its technology, gets acquired, or relists somewhere else, those options become valuable again.

For a non-insider employee, the math is less clear. If you're a scientist or operations person at a private Norwegian biotech, and your compensation includes options you can't sell, those options are essentially deferred compensation that depends on a future acquisition. They're not worthless. But they're not liquid, and they're not the same financial instrument they were before delisting.

The dilution math

The company has about 111.5 million shares outstanding. The 1.3 million new options, if all exercised, would create 1.3 million additional shares — roughly a 1.2% dilution to existing shareholders. That is modest. Not trivial, but modest.

If you're an existing shareholder who hasn't sold yet, and who still holds through delisting, your ownership percentage will drop by about 1.2% if all these options are exercised. Whether that happens depends on the exercise price relative to whatever private valuation emerges later. If the company is worth more than the exercise price, someone will exercise. If not, the options expire unexercised and there's no dilution.

This is the basic structure of every share option grant. The novelty here is only the timing: granting options that will vest in a world without a public market.

What comes before this

The August 31 grant is not the first time EXACT Therapeutics has restructured its equity incentives recently. On November 24, 2025, the company introduced a new long-term incentive program and granted approximately 1 million share options to insiders and employees. That program appears to be the same framework under which these latest options were issued.

Between those two grants, the company also went through a significant capital raise. In December 2024, EXACT Therapeutics completed a NOK 145 million private placement with GE Healthcare as the cornerstone investor. The placement included warrants, and in February 2026, GE Medical Holding AB exercised all of its warrants, bringing in NOK 33 million in gross proceeds for the company.

So the sequence is: raise capital (with warrant upside for the lead investor) → grant a large option program to insiders → exercise the warrants (diluting everyone, including the new option holders) → announce delisting → grant another option program → delist.

The warrants exercised first, before the options were fully vested. That order matters because warrant exercise increases the share count and can push the stock price down — making options that were granted at a higher price potentially underwater. It's not that the company did anything wrong. It's that these instruments interact, and the sequence determines who gets diluted first and who gets the benefit of a lower price.

The bigger picture

The underlying question for a U.S. investor watching this is: what does it mean to hold a share in a company that is voluntarily leaving the public market?

After October 12, EXACT Therapeutics becomes what it always was economically: a private clinical-stage biotech with a drug platform, no revenue, and a cash burn of roughly NOK 85 million a year. The public listing added compliance costs, reporting deadlines, and quarterly scrutiny on top of all that. The board decided the costs were greater than the benefits.

That is a rational calculation for a company this small. When your market capitalization is $6.5 million and your annual burn is roughly $6.8 million, you're not exactly generating institutional investor interest that justifies the compliance apparatus. The listing was a financing mechanism — useful for the private placement, useful for the warrant structure, useful for credibility. But at some point, the listing itself becomes an expense line item, and the company cuts it.

The share option grant is part of that same transition. The company is converting its compensation structure from a public-market instrument to a private-market one. The options don't change their legal terms. They change their economic reality. They go from being tradable claims to being long-term stakes that depend on a future liquidity event.

What to watch

If you still own EXACT Therapeutics shares, you have about ten trading days left. The stock is illiquid, with daily volumes in the low thousands. It's unlikely the August 31 option grant will move the price much either direction — there aren't enough participants left in this trade for a reaction.

The structural questions are:

• Where do these shares go? After delisting, Norwegian companies typically transfer to a retail market (FOT) where trading is extremely thin, or simply become untraded. Existing shareholders own real equity, but selling it becomes difficult.
• What happens to the options? They remain outstanding, governed by the company's option plan. Vesting continues. Exercise happens whenever the holder decides — but the exercised shares are private shares with no public market.
• When does liquidity return? Only if the company relists, gets acquired, or raises new capital through a private equity process that includes a secondary sale for existing holders.

None of those are immediate. EXACT Therapeutics is developing a medical device platform called Acoustic Cluster Therapy (ACT) — an ultrasound-based drug enhancement system — and its clinical programs are in Phase 2. The next catalyst is clinical data, not capital structure.

But understanding the capital structure helps you understand who has skin in the game, at what price, and through what mechanism. The new option holders — mostly insiders — are telling you they expect to be around for a while. Whether that conviction is worth anything depends on the science, not the plumbing. But the plumbing tells you who's committed, who's diluted, and what instrument they're holding when the lights come back on.